VIR_logo_large.jpg
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
08 mars 2023 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
28 févr. 2023 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
23 févr. 2023 16h05 HE | Vir Biotechnology, Inc.
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact – – $1.5 billion of...
VIR_logo_large.jpg
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
22 févr. 2023 08h30 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final...
VIR_logo_large.jpg
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
16 févr. 2023 16h05 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter...
VIR_logo_large.jpg
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
16 févr. 2023 08h30 HE | Vir Biotechnology, Inc.
– Experienced biotech executive brings more than 20 years of financial leadership to Vir – – Howard Horn departing to pursue next chapter; will remain in an advisory role through a brief transition...
VIR_logo_large.jpg
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
13 févr. 2023 16h45 HE | Vir Biotechnology, Inc.
– Vir to continue advancing next-generation COVID-19 solutions independently or with other partners – – The Companies will continue working together to ensure ongoing access to sotrovimab for...
VIR_logo_large.jpg
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
25 janv. 2023 08h29 HE | Vir Biotechnology, Inc.
– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel...
VIR_logo_large.jpg
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h05 HE | Vir Biotechnology, Inc.
– Critical Phase 2 readouts anticipated in 2023 for three advanced programs – hepatitis B, hepatitis D and influenza – – Strong balance sheet expected to fund Vir’s robust portfolio through major...
VIR_logo_large.jpg
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
21 déc. 2022 08h00 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking...